| pubmed-article:2456681 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2456681 | lifeskim:mentions | umls-concept:C0151636 | lld:lifeskim |
| pubmed-article:2456681 | lifeskim:mentions | umls-concept:C0442027 | lld:lifeskim |
| pubmed-article:2456681 | lifeskim:mentions | umls-concept:C0071144 | lld:lifeskim |
| pubmed-article:2456681 | lifeskim:mentions | umls-concept:C0443252 | lld:lifeskim |
| pubmed-article:2456681 | pubmed:issue | 2 Pt 1 | lld:pubmed |
| pubmed-article:2456681 | pubmed:dateCreated | 1988-9-2 | lld:pubmed |
| pubmed-article:2456681 | pubmed:abstractText | Pirmenol is an investigational type 1A antiarrhythmic drug the long-term efficacy of which has not been fully determined. Therefore the long-term efficacy of oral pirmenol in suppressing ventricular premature depolarizations (VPDs) was assessed in an open-label, dose-titration study. Twelve patients (eight men and four women; mean age 57 +/- 12 years) were treated for 24 to 36 months (mean 33 +/- 4). Seven had structural heart disease (three valvular heart disease, two ischemic heart disease, and two hypertensive heart disease) and five did not. The mean left ventricular ejection fraction was 0.63 +/- 0.13. Exclusion criteria included less than 30 VPDs/hr, greater than 15 beats of ventricular tachycardia (VT), or prior failure of more than two antiarrhythmic drugs. Drug efficacy was assessed by 24-hour ambulatory ECG monitoring performed every 3 months during the first year, every 4 months during the second year, and at 6-month intervals during the third year. The mean hourly frequency of VPDs during the placebo phase was 732 +/- 608. Seven patients (58%) were treated successfully with effective (greater than 75%) long-term suppression of VPDs. Two patients (17%) had a partial response with effective suppression of VPDs for the first 16 months and 5 months of treatment, respectively. Three patients failed to show consistent suppression of VPDs while receiving pirmenol. The daily dose of pirmenol ranged from 200 to 500 mg (mean 317 +/- 94 mg at the beginning of the study and 375 +/- 97 mg at the end). No proarrhythmic effects were identified during long-term treatment, and none of the patients withdrew from the study prematurely.(ABSTRACT TRUNCATED AT 250 WORDS) | lld:pubmed |
| pubmed-article:2456681 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2456681 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2456681 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:2456681 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2456681 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2456681 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2456681 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2456681 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:2456681 | pubmed:issn | 0002-8703 | lld:pubmed |
| pubmed-article:2456681 | pubmed:author | pubmed-author:NelsonS DSD | lld:pubmed |
| pubmed-article:2456681 | pubmed:author | pubmed-author:MoradyFF | lld:pubmed |
| pubmed-article:2456681 | pubmed:author | pubmed-author:JohnsonTT | lld:pubmed |
| pubmed-article:2456681 | pubmed:author | pubmed-author:CreveyB JBJ | lld:pubmed |
| pubmed-article:2456681 | pubmed:author | pubmed-author:SchmaltzSS | lld:pubmed |
| pubmed-article:2456681 | pubmed:author | pubmed-author:KouW HWH | lld:pubmed |
| pubmed-article:2456681 | pubmed:author | pubmed-author:de BuitleirMM | lld:pubmed |
| pubmed-article:2456681 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2456681 | pubmed:volume | 116 | lld:pubmed |
| pubmed-article:2456681 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2456681 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2456681 | pubmed:pagination | 379-84 | lld:pubmed |
| pubmed-article:2456681 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:2456681 | pubmed:meshHeading | pubmed-meshheading:2456681-... | lld:pubmed |
| pubmed-article:2456681 | pubmed:meshHeading | pubmed-meshheading:2456681-... | lld:pubmed |
| pubmed-article:2456681 | pubmed:meshHeading | pubmed-meshheading:2456681-... | lld:pubmed |
| pubmed-article:2456681 | pubmed:meshHeading | pubmed-meshheading:2456681-... | lld:pubmed |
| pubmed-article:2456681 | pubmed:meshHeading | pubmed-meshheading:2456681-... | lld:pubmed |
| pubmed-article:2456681 | pubmed:meshHeading | pubmed-meshheading:2456681-... | lld:pubmed |
| pubmed-article:2456681 | pubmed:meshHeading | pubmed-meshheading:2456681-... | lld:pubmed |
| pubmed-article:2456681 | pubmed:meshHeading | pubmed-meshheading:2456681-... | lld:pubmed |
| pubmed-article:2456681 | pubmed:meshHeading | pubmed-meshheading:2456681-... | lld:pubmed |
| pubmed-article:2456681 | pubmed:meshHeading | pubmed-meshheading:2456681-... | lld:pubmed |
| pubmed-article:2456681 | pubmed:meshHeading | pubmed-meshheading:2456681-... | lld:pubmed |
| pubmed-article:2456681 | pubmed:meshHeading | pubmed-meshheading:2456681-... | lld:pubmed |
| pubmed-article:2456681 | pubmed:meshHeading | pubmed-meshheading:2456681-... | lld:pubmed |
| pubmed-article:2456681 | pubmed:meshHeading | pubmed-meshheading:2456681-... | lld:pubmed |
| pubmed-article:2456681 | pubmed:meshHeading | pubmed-meshheading:2456681-... | lld:pubmed |
| pubmed-article:2456681 | pubmed:meshHeading | pubmed-meshheading:2456681-... | lld:pubmed |
| pubmed-article:2456681 | pubmed:year | 1988 | lld:pubmed |
| pubmed-article:2456681 | pubmed:articleTitle | Long-term efficacy of oral pirmenol in suppressing ventricular premature depolarizations. | lld:pubmed |
| pubmed-article:2456681 | pubmed:affiliation | Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor 48109-0022. | lld:pubmed |
| pubmed-article:2456681 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2456681 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:2456681 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
